

Effective date: 12/1/2022
Last Reviewed: 9/2022, 6/2023
Scope: Medicaid

VTAMA (tapinarof) cream

POLICY

I. INDICATIONS

The indications below including FDA-approved indications and compendial uses are considered a covered benefit provided that all the approval criteria are met, and the member has no exclusions to the prescribed therapy.

A. FDA-Approved Indications

1. Plaque psoriasis in adults.

All other indications are considered experimental/investigational and not medically necessary.

II. DOCUMENTATION

Submission of the following information is necessary to initiate the prior authorization review:

A. Initial requests:

1. Chart notes or medical record documentation of affected area(s) and percentage of body surface area (BSA) affected.
2. Chart notes, medical record documentation, or claims history supporting previous medications tried (if applicable), including response to therapy. If therapy is not advisable, documentation of clinical reason to avoid therapy.

B. Continuation requests:

1. Chart notes or medical record documentation of decreased body surface area (BSA) affected and/or improvement in signs and symptoms.

III. CRITERIA FOR INITIAL APPROVAL

Plaque Psoriasis (PsO)

Initial authorization of 12 months may be granted for members when the following criteria are met:

1. Member is 18 years of age or older, diagnosed with plaque psoriasis
2. BSA affected is between 3-20%. Documentation of BSA affected is provided.
3. Vtama is prescribed by, or in consultation with, a specialist in dermatology or rheumatology.
4. Member experienced an inadequate treatment response to at least a 2-4 consecutive week trial within the last 12 months of a high or ultra-high potency topical corticosteroid (e.g., augmented betamethasone, clobetasol). Contraindications, adverse effects and/or intolerance must be documented.
5. Member experienced an inadequate treatment response or intolerance from two of the following therapies in combination with a topical corticosteroid within the last 12 months. Contraindications, adverse effects and/or intolerance must be documented.
 - a. Topical calcineurin inhibitors (e.g., tacrolimus ointment, pimecrolimus cream)
 - b. Topical vitamin D analogs (e.g., calcipotriene 0.005% ointment, cream, solution)
 - c. Topical retinoid (e.g., tazarotene cream 0.1%)
 - d. Phototherapy

Effective date: 12/1/2022
Last Reviewed: 9/2022, 6/2023
Scope: Medicaid

- e. Oral systemic non-biologic drugs (e.g., methotrexate, cyclosporine, or acitretin)
- 6. Member experienced an inadequate treatment response or intolerance from Zoryve (roflumilast) cream within the last 12 months. Contraindications, adverse effects and/or intolerance must be documented.
 - a. If the member is switching from a biologic for psoriasis treatment, they are not required to trial Zoryve before Vtama.
- 7. Vtama will not be used concomitantly with Zoryve (roflumilast) cream, any biologic DMARD (e.g., adalimumab, infliximab), or any targeted synthetic DMARD (e.g., apremilast).

IV. CONTINUATION OF THERAPY

Authorization of 12 months may be granted for all members who are using the requested medication for plaque psoriasis when the following criteria are met:

- 1. Member achieves or maintains a positive clinical response as evidenced by improvement in signs and symptoms of the condition when any of the following is met:
 - a. Reduction in body surface area (BSA) affected from baseline
 - b. Improvement in signs and symptoms from baseline (e.g., itching, redness, flaking, scaling, burning, cracking, pain)
- 2. Vtama will not be used concomitantly with Zoryve (roflumilast) cream, any biologic DMARD (e.g., adalimumab, infliximab), or any targeted synthetic DMARD (e.g., apremilast).

V. QUANTITY LIMIT

- 1. 60 grams per 30 days

VI. REFERENCES

- 1. Vtama (tapinarof) cream, for topical use. US FDA approved product information; Long Beach, CA: Dermavant Sciences, Inc; May 2022. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215272s000lbl.pdf (Accessed on June 20, 2022).